This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It? This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It? · Barrons.com · Getty Images Mackenzie Tatananni October 7, 2026 2 min read ABBV AZN VRXA Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ Continue Reading Terms and Privacy Policy Your Privacy Choices More Info
